Who
Richard J. Rodgers
Director
Company insider
Files Form 4 as: Director, Novavax; Director, Ardelyx; Interim CEO and President, Opus Genetics; Director, Sagimet Biosciences; Executive VP & CFO, Tesaro; Senior Vice President and CFO, Abraxis BioScience; Sr. VP and Controller, Mgi Pharma.
In numbers
- Trades disclosed
- 118
- Buys
- 1
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 7
- Companies where not an officer
- 3
- First trade
- 15 Jul 2006
- Last trade
- 20 Jun 2026
- Last filed
- 23 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 20 Jun 2026filed 23 Jun 2026 | NVAX NovavaxBiotechnology | SEC FORM 4 Code M | —18,880 | filing |
| 20 Jun 2026filed 23 Jun 2026 | NVAX Novavaxoption or derivative · Biotechnology | SEC FORM 4 Code M | —18,880 at $0.00 | filing |
| 20 Jun 2026filed 23 Jun 2026 | NVAX Novavaxoption or derivative · Biotechnology | SEC FORM 4 Code M | —18,880 at $0.00 | filing |
| 20 Jun 2026filed 23 Jun 2026 | NVAX NovavaxBiotechnology | SEC FORM 4 Code M | —18,880 | filing |
| 18 Jun 2026filed 23 Jun 2026 | NVAX Novavaxoption or derivative · Biotechnology | SEC FORM 4 Code A | —21,270 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | NVAX Novavaxoption or derivative · Biotechnology | SEC FORM 4 Code A | —14,180 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | NVAX Novavaxoption or derivative · Biotechnology | SEC FORM 4 Code A | —21,270 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | NVAX Novavaxoption or derivative · Biotechnology | SEC FORM 4 Code A | —14,180 at $0.00 | filing |
| 16 Jun 2026filed 18 Jun 2026 | ARDX ArdelyxBiotechnology | SEC FORM 4 Code A | —26,455 at $0.00 | filing |
| 16 Jun 2026filed 18 Jun 2026 | ARDX Ardelyxoption or derivative · Biotechnology | SEC FORM 4 Code A | —39,715 at $0.00 | filing |
| 16 Jun 2026filed 18 Jun 2026 | ARDX Ardelyxoption or derivative · Biotechnology | SEC FORM 4 Code A | —39,715 at $0.00 | filing |
| 16 Jun 2026filed 18 Jun 2026 | ARDX ArdelyxBiotechnology | SEC FORM 4 Code A | —26,455 at $0.00 | filing |
| 20 Apr 2026filed 22 Apr 2026 | IRD Opus GeneticsBiotechnology | SEC FORM 4 Code A | —24,367 at $0.00 | filing |
| 20 Apr 2026filed 22 Apr 2026 | IRD Opus GeneticsBiotechnology | SEC FORM 4 Code A | —24,367 at $0.00 | filing |
| 29 Oct 2025filed 30 Oct 2025 | NVAX Novavaxoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,800 at $0.00 | filing |
| 29 Oct 2025filed 30 Oct 2025 | NVAX NovavaxBiotechnology | SEC FORM 4 Code M | —3,800 | filing |
| 20 Jun 2025filed 24 Jun 2025 | NVAX Novavaxoption or derivative · Biotechnology | SEC FORM 4 Code A | $182K28,326 at $6.42 | filing |
| 20 Jun 2025filed 24 Jun 2025 | NVAX Novavaxoption or derivative · Biotechnology | SEC FORM 4 Code A | —18,884 at $0.00 | filing |
| 18 Jun 2025filed 23 Jun 2025 | ARDX Ardelyxoption or derivative · Biotechnology | SEC FORM 4 Code A | —54,059 at $0.00 | filing |
| 18 Jun 2025filed 23 Jun 2025 | ARDX ArdelyxBiotechnology | SEC FORM 4 Code A | —21,468 at $0.00 | filing |
News
Opus Genetics Announces FDA Approval of Phentolamine Ophthalmic Solution 0.75% for the Treatment of PresbyopiaIRD · manilatimes.net · 16 Oct 2026Opus Genetics Presents Positive Clinical Data from OPGx-BEST1 and OPGx-LCA5 Gene Therapy Programs at Retina in Rio 2026IRD · manilatimes.net · 15 Oct 2026Opus Genetics to Present at the Chardan Annual Healthcare ConferenceIRD · manilatimes.net · 13 Oct 2026
0 headlines in the last 90 days name Richard J. Rodgers; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.